Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.150
-0.060 (-2.71%)
At close: Mar 31, 2025, 4:00 PM
2.220
+0.070 (3.26%)
After-hours: Mar 31, 2025, 6:06 PM EDT
Soligenix Employees
As of December 31, 2023, Soligenix had 15 total employees, including 13 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$7,958
Profits / Employee
-$551,105
Market Cap
6.78M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SNGX News
- 6 days ago - IBN Initiates Coverage of Soligenix Inc. - GlobeNewsWire
- 6 days ago - Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PRNewsWire
- 10 days ago - Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - PRNewsWire
- 25 days ago - HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - PRNewsWire
- 7 weeks ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire
- 2 months ago - Soligenix to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire
- 3 months ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire